# Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

> **NCT05028634** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 63 (actual)

## Conditions studied

- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** Tetanus, diphtheria, and acellular pertussis vaccine
- **BIOLOGICAL:** Pneumococcal polysaccharide vaccine
- **BIOLOGICAL:** Seasonal influenza vaccine

## Key facts

- **NCT ID:** NCT05028634
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2023-11-15
- **Final completion:** 2023-11-15
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028634, "Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05028634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*